Literature DB >> 1616049

In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide blockade.

C C Sieber1, R J Groszmann.   

Abstract

The endothelial cell plays an important role in the local control of vascular smooth muscle tone. Portal hypertension is accompanied by systemic vasodilatation and a decreased response to vasoconstrictors, changes especially evident in the superior mesenteric arterial bed. To evaluate a possible effect of the locally released endothelium-derived relaxing factor nitric oxide (NO), we tested the effect of NO blockade in in vitro perfused superior mesenteric arterial beds of normal (sham) and portal hypertensive (PVL) rats, induced by partial portal vein ligation. A significant (n = 7/group; P = 0.02) hyporeactivity to the vasoconstrictive properties of the alpha-adrenoceptor agonist methoxamine (3 x 10(-6) to 3 x 10(-4) M) was prevented by blocking NO formation in PVL compared with sham rats, using the stereospecific biosynthesis antagonist N omega-nitro-L-arginine (10(-4) M, n = 7/group; NS for all methoxamine concentrations tested). This effect was reversed by the NO precursor L-arginine (10(-3) M, n = 5/group). In conclusion, these in vitro results in mesenteric vessels demonstrate that 1) portal hypertension is accompanied by a hyporeactivity to the vasopressor methoxamine and 2) locally released NO in this preparation is responsible for the decreased vasoconstrictive response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1616049     DOI: 10.1152/ajpgi.1992.262.6.G996

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  12 in total

1.  Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility.

Authors:  R Wiest; S Das; G Cadelina; G Garcia-Tsao; S Milstien; R J Groszmann
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 2.  Animal models of portal hypertension.

Authors:  Juan-G Abraldes; Marcos Pasarín; Juan-Carlos García-Pagán
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

3.  Anatomical differences in responsiveness to vasoconstrictors in the mesenteric veins from normal and portal hypertensive rats.

Authors:  L Moreno; M A Martínez-Cuesta; J M Piqué; J Bosch; J V Esplugues
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

4.  Murine study of portal hypertension associated endothelin-1 hypo-response.

Authors:  Nicholas Theodorakis; Mary Maluccio; Nicholas Skill
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

5.  Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites.

Authors:  M Bolognesi; D Sacerdoti; M Di Pascoli; P Angeli; S Quarta; A Sticca; P Pontisso; C Merkel; A Gatta
Journal:  Gut       Date:  2005-06-10       Impact factor: 23.059

6.  Hepatocyte nitric oxide production is induced by Kupffer cells.

Authors:  Y Shiratori; K Ohmura; Y Hikiba; M Matsumura; T Nagura; K Okano; K Kamii; M Omata
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

7.  Therapeutic potential of targeting the renin angiotensin system in portal hypertension.

Authors:  Chandana B Herath; Josephine A Grace; Peter W Angus
Journal:  World J Gastrointest Pathophysiol       Date:  2013-02-15

8.  Heat shock protein 90 is responsible for hyperdynamic circulation in portal hypertensive rats.

Authors:  Jian-Hua Ai; Zhen Yang; Fa-Zu Qiu; Tong Zhu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

9.  Role of protein kinase C in mesenteric pressor responses of rats with portal hypertension.

Authors:  N M Atucha; M C Ortíz; C Martínez; T Quesada; J García-Estañ
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

10.  Vasoconstrictor responsiveness of the rat mesenteric arterial bed in cirrhosis.

Authors:  V Ralevic; R T Mathie; K P Moore; G Burnstock
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.